Predicting relapse after achieving a functional cure for chronic hepatitis B (CHB) using baseline HBsAg and end-of-treatment HBsAb levels

• Published in: Scientific reports Vol. 15; no. 1; pp. 13873 - 9
• Main Authors: Han, Lianxiu, Wang, Zilong, Kang, Luyang, Cui, Xiaoling, Li, Yi, Yin, Huafa, Gao, Yufeng, Li, Jiabin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 22.04.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/255; 692/699/255; Adult; Antiviral Agents - therapeutic use; Female; HBsAb; HBsAg; Hepatitis; Hepatitis B; Hepatitis B Antibodies - blood; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis B Surface Antigens - immunology; Hepatitis B virus - immunology; Hepatitis B, Chronic - blood; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - immunology; Hepatitis B, Chronic - virology; Humanities and Social Sciences; Humans; Kaplan-Meier Estimate; Kaplan–Meier; Logistic regression analysis; Male; Middle Aged; multidisciplinary; Nomogram; Patients; Prediction models; Recurrence; Regression analysis; Retrospective Studies; Risk Factors; Science; Science (multidisciplinary); Survival; Survival analysis; Treatment Outcome; HBsAg; Logistic regression analysis; HBsAb; Kaplan–Meier; Nomogram

Among the factors influencing relapse after clinical cure of chronic hepatitis B(CHB). There is no standardization of baseline HBsAg levels and end-of-treatment HBsAb levels. This multicenter, retrospective study enrolled 136 patients who achieved functional cure from June 2019 to December 2023, and...